Smith, Moore & Co’s Amgen AMGN Stock Holding History

Smith, Moore & Co’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.07M	Buy	5,882 +698	+13%	+$249K	0.15%	129
2025 Q4	$1.7M	Sell	5,184 -1,706	-25%	-$541K	0.13%	140
2025 Q3	$1.94M	Buy	6,890 +128	+2%	+$37.1K	0.15%	130
2025 Q2	$1.89M	Sell	6,762 -173	-2%	-$49K	0.16%	124
2025 Q1	$2.16M	Buy	6,935 +177	+3%	+$52.3K	0.2%	106
2024 Q4	$1.76M	Sell	6,758 -825	-11%	-$245K	0.16%	122
2024 Q3	$2.44M	Buy	7,583 +587	+8%	+$192K	0.23%	89
2024 Q2	$2.19M	Buy	6,996 +2,035	+41%	+$598K	0.23%	92
2024 Q1	$1.41M	Buy	4,961 +109	+2%	+$31.9K	0.15%	130
2023 Q4	$1.4M	Sell	4,852 -40	-0.8%	-$10.9K	0.16%	118
2023 Q3	$1.31M	Sell	4,892 -530	-10%	-$132K	0.17%	114
2023 Q2	$1.2M	Buy	5,422 +238	+5%	+$55.2K	0.15%	122
2023 Q1	$1.25M	Sell	5,184 -65	-1%	-$16K	0.17%	113
2022 Q4	$1.38M	Sell	5,249 -854	-14%	-$229K	0.19%	99
2022 Q3	$1.38M	Sell	6,103 -222	-4%	-$53.8K	0.21%	96
2022 Q2	$1.54M	Buy	6,325 +100	+2%	+$24.5K	0.24%	91
2022 Q1	$1.5M	Sell	6,225 -89	-1%	-$20.4K	0.21%	94
2021 Q4	$1.42M	Buy	6,314 +413	+7%	+$87.2K	0.2%	97
2021 Q3	$1.25M	Buy	5,901 +130	+2%	+$29.9K	0.19%	101
2021 Q2	$1.41M	Buy	5,771 +90	+2%	+$22.1K	0.21%	89
2021 Q1	$1.41M	Buy	5,681 +3,500	+160%	+$835K	0.23%	88
2020 Q4	$501K	Buy	2,181 +71	+3%	+$16.4K	0.09%	202
2020 Q3	$536K	Sell	2,110 -468	-18%	-$116K	0.11%	184
2020 Q2	$608K	Buy	2,578 +209	+9%	+$47.7K	0.13%	139
2020 Q1	$480K	Sell	2,369 -32	-1%	-$6.99K	0.13%	156
2019 Q4	$579K	Sell	2,401 -51	-2%	-$11.2K	0.12%	154
2019 Q3	$474K	Buy	2,452 +563	+30%	+$108K	0.1%	180
2019 Q2	$348K	Buy	1,889 +513	+37%	+$91.9K	0.08%	233
2019 Q1	$261K	Sell	1,376 -499	-27%	-$95.3K	0.06%	261
2018 Q4	$365K	Buy	1,875 +447	+31%	+$87.2K	0.1%	205
2018 Q3	$296K	Buy	1,428 +53	+4%	+$10.4K	0.07%	255
2018 Q2	$254K	Buy	+1,375	New	+$243K	0.06%	273
2018 Q1	–	Sell	-2,346	Closed	-$408K	–	326
2017 Q4	$408K	Buy	2,346 +2	+0.1%	+$354	0.11%	182
2017 Q3	$437K	Buy	2,344 +176	+8%	+$31.2K	0.12%	165
2017 Q2	$373K	Buy	2,168 +182	+9%	+$29.6K	0.13%	165
2017 Q1	$326K	Buy	1,986 +213	+12%	+$35.4K	0.12%	170
2016 Q4	$259K	Buy	1,773 +195	+12%	+$29.3K	0.1%	187
2016 Q3	$263K	Sell	1,578 -667	-30%	-$113K	0.11%	179
2016 Q2	$342K	Buy	+2,245	New	+$349K	0.14%	136

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Smith, Moore & Co's AMGN Position: Q1 2026 in Review

Smith, Moore & Co increased its Amgen (AMGN) stake by 13% in Q1 2026, buying an estimated $249K and bringing the position to 5,882 shares worth $2.07M. The position accounts for 0.15% of the portfolio, ranked #129.

Smith, Moore & Co first reported a position in AMGN in Q2 2016 and has held it in 39 quarters since. The position peaked at $2.44M in Q3 2024. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

Smith, Moore & Co held 5,882 shares of Amgen worth $2.07M as of Q1 2026.
Smith, Moore & Co bought 698 Amgen shares in Q1 2026, an estimated $249K.
Amgen made up 0.15% of Smith, Moore & Co's portfolio in Q1 2026, its #129 holding.
Smith, Moore & Co first reported a position in Amgen in Q2 2016 and has held it in 39 quarters since.
Smith, Moore & Co's Amgen position peaked at $2.44M in Q3 2024.
3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.